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ABSTRACT
Objective: To investigate the effectiveness of statin ther-
apy and to compare the effectiveness results of this study
with the reported efﬁcacy of the corresponding data from
randomized clinical trials in a moderate-to-high risk cor-
onary heart disease (CHD) managed care population.
Methods: Subjects, ≥18 years old, with a new hyperlipi-
demia diagnosis or a new prescription claim for a lipid-
lowering medication (LLM) between January 1, 1999 and
March 31, 2001 were followed for 12 months. Subjects
were classiﬁed into six medication categories of LLM use
based partly on efﬁcacy levels on package inserts. CHD
risk factors were measured in the 24-month period prior,
and subjects were required to have an established CHD or
a CHD-related condition, or have two or more CHD risk
factors.
Results: The study population consisted of 39,124 hyper-
lipidemic subjects with moderate-to-high CHD risk;
22,048 (56.4%) were untreated with LLMs. Absolute
mean low-density lipoprotein cholesterol (LDL-C) reduc-
tions ranged from a 32 mg/dL decrease in the low-efﬁcacy
groups to a 57 mg/dL decrease in the high efﬁcacy statin
group; percent reductions ranged from a 19% reduction
from baseline to a 32% reduction from baseline, respec-
tively. Less than half of subjects (47%) reached LDL goals
set forth by NCEP Adult Treatment Panel (ATP III) guide-
lines, however, the rate of reaching goal increased as sta-
tin efﬁcacy increased.
Conclusions: While a dose–response relationship was
observed, the effectiveness of statin therapy was less than
stated in package labeling and only 72% of the users of
the highest efﬁcacy statins reached their ATP III goal.
LLM use was inconsistent with that recommended by the
NCEP ATP III CHD risk assessment. Hyperlipidemia
treatment in the managed care setting remains in need of
improvement.
Keywords: ATP III, CHD risk, hyperlipidemia, lipid-
lowering, managed care, statin.
Background
Cardiovascular disease (CVD) is the leading cause
of morbidity and mortality in the United States.
Currently, there are 61.8 million Americans with
CVD. Approximately 12.9 million are afﬂicted with
coronary heart disease (CHD) [1] and more than a
million new CHD events occurred in 2002. Nation-
ally, 2003 estimates are that CVD and stroke
account for $351.8 billion in direct and indirect
costs, with $129.9 billion attributable to CHD. The
estimated total direct costs of CHD are $61.2 bil-
lion with hospitalization as the major cost driver
costing $34.2 billion annually [2]. Benchmark stud-
ies in managed care populations indicate that the
average cost per enrollee per year for CHD is
approximately $4000 [3].
Decades of epidemiologic research have demon-
strated a causal relation between high total choles-
terol levels, particularly increases in low-density
lipoprotein cholesterol (LDL-C), and the risk of
CHD [4]. The beneﬁcial effects of a hydroxymeth-
ylglutaryl coenzyme A (HMG-CoA) reductase
inhibitor (or statin) in reduction of CHD morbidity
and mortality have been well established [5–16].
Despite the availability of these effective therapies,
CHD remains highly prevalent. The high incidence
and prevalence of CHD may be due to the contin-
uing high cholesterol levels. The National Choles-
terol Education Program (NCEP) Adult Treatment
Panel III (ATP III) recommends initiation of lipid-
lowering therapy in conjunction with therapeutic
life style change for patients at high risk for CHD as
well those with established disease. The ATP III
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guidelines update the previous NCEP recommenda-
tions and suggest “Recommendations for special
populations such as patients with CHD, patients at
high risk for developing CHD, patients with diabe-
tes, women, older Americans, young adults, and
racial and ethnic groups . . .” [17].
There has been very little change in total choles-
terol levels in more than a decade despite public
awareness campaigns to reduce cholesterol. In a
1999–2000 National Health and Nutrition Exami-
nation Survey (NHANES), the average cholesterol
level among US adults was 203 mg/dL of blood.
The ﬁndings, published by the American Heart
Association (AHA) journal Circulation, are based
on cholesterol levels of about 4000 men and women
who were participating in the NHANES survey
from 1999 to 2000. Their cholesterol levels were
compared with national data collected from more
than 15,000 people during a similar survey con-
ducted between 1988 and 1994. For all adults, the
age-adjusted average total cholesterol concentration
decreased from 205 mg/dL to 203 mg/dL between
the two surveys. Comparing the 1988–1994
NHANES survey to the 1976–1980 NHANES sur-
vey, age-adjusted cholesterol levels dropped by
8 mg/dL [18].
A review of research done in managed care set-
tings over the last decade reveals a large and con-
sistent performance gap in cholesterol management,
in which most at-risk subjects are undertreated
[19–23]. Studies of statin therapy in actual clinical
practice  have  identiﬁed  a  performance  gap  in
the pharmacological management of dyslipidemia
when compared with the expectations generated by
the results of clinical trials of these therapies. In a
study of simvastatin, atorvastatin, and pravastatin
patients who were enrolled in a group cardiology
practice with case management, Frolkis and col-
leagues noted that subjects achieved only 79% of
the expected reduction in LDL-C based on package
labeling. The authors attributed this failure to
achieve expected levels of LDL-C reduction on var-
iations in patient compliance with therapy (both
medication and dietary recommendations) [24].
Pearson et al. noted that only 38% of subjects
enrolled in the Lipid Treatment Assessment Project,
who were receiving lipid-lower therapy (including
statins), reached NCEP-speciﬁed targets for LDL-C.
These authors cite the failure of subjects to be pre-
scribed adequate treatments as a primary cause of
the failure to achieve LDL-C goals [19].
The current research adds to the literature by
examining the management of dyslipidemia in real-
world clinical practice based on ATP III guidelines
and current data from a national managed care
organization. The objectives of this study were: 1)
to assess the effectiveness of lipid-lowering thera-
pies in a real-world setting; and 2) to compare the
effectiveness results of this study with the reported
efﬁcacy of the corresponding data from randomized
clinical trials (RCTs). Effectiveness was measured
by the percent reduction in LDL-C and by the pro-
portion of subjects reaching an ATP III-established
LDL-C goal.
Methods
Data Source
The current study was based on claims data from
several health plans located in various geographic
areas of the United States that were afﬁliated with
Ingenix, Inc. The study sample was selected from a
database which contains more than 5 million
annual covered lives, and was limited to subjects
≥18 years of age with integrated laboratory results,
pharmacy, and medical claims data with service
dates from January 1, 1997 to March 31, 2001. All
plans were noncapitated, managed fee-for-service
plans. Laboratory results were not available in the
database before January 1, 1999 and cholesterol
results were available for approximately 10% of
subjects after January 1, 1999. The database com-
plies with the Health Insurance Portability and
Accountability Act of 1996 (HIPAA) and Ingenix
uses encrypted unique patient identiﬁers to integrate
laboratory results, pharmacy, and medical claims
data.
Subject Inclusion Criteria and Study Timeline
An  index  date  was  deﬁned  as  the  ﬁrst  indicator
of hyperlipidemia between January 1, 1999 and
March 31, 2001 (Fig. 1). Indicators of hyperlipi-
demia included the presence of a hyperlipidemia
diagnosis on a medical claim (ICD-9-CM codes:
272.0x-272.2x, 272.4x, or 272.9x) or any pre-
scription claim for a lipid-lowering medication
(LLM) (therapeutic niacin, ﬁbric-acid derivatives
[FAD], bile acid sequestrants [BAS], or HMG-CoA
reductase inhibitors [statins]) during the capture
period. Subjects were not required to have an LLM
claim to be identiﬁed as hyperlipidemic, and LLM
use may have begun after the index date. Subjects
were deﬁned as new hyperlipidemic subjects based
on an absence of a hyperlipidemia diagnosis and
LLM use in the 24 months before the index date.
Health-care resource utilization data records 12
months after the index date were analyzed to assess
outcomes. Subjects were required to be continu-
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ously enrolled in their health plan for 24 months
before and 12 months after the index date.
Established CHD or Moderate–High CHD Risk 
Factors and LDL-C Goals
Subjects were categorized into two risk groups based
on health-care resource utilization data in the 24-
month period before the index date. Subjects with
CHD, diabetes, or other forms of atherosclerotic
disease (acute myocardial infarction, other acute
and subacute forms of ischemic heart disease, angina
pectoris, other forms of chronic ischemic heart dis-
ease, stroke, peripheral vascular disease, and athero-
sclerosis) were considered to be at high risk for
CHD. Subjects with ≥2 CHD risk factors (i.e., his-
tory of smoking or current smoker, hypertension,
low HDL cholesterol (<40 mg/dL), family history of
ischemic heart disease, and age (male ≥45; female
≥55 years of age) were considered at moderate risk
for CHD. HDL ≥60 counts as a negative risk factor:
its presence removes one risk factor from the total
count. Subjects without an established CHD, a
CHD-related condition, or two or more CHD risk
factors were excluded from the analyses.
Because the full 10-year Framingham risk score
cannot be calculated using administrative data, we
assigned ATP III LDL-C goals of <100 mg/dL and
<130 mg/dL to the high- and moderate-risk groups,
respectively, using available ICD-9 codes and phar-
macy claim records in the 24 months before the
index date.
Lipid-Lowering Medication Classiﬁcation
The objectives of the study were to examine the
effectiveness of LLM medications by assessing the
LDL-C reductions achieved in actual managed care
practice setting and to compare the level of LDL-C
reduction to RCT results. To facilitate this analysis,
mutually exclusive statin medication groups were
deﬁned based, in part, on the magnitude of expected
percent reduction in LDL-C levels ascertained from
the package insert for each drug. Subjects were cat-
egorized into efﬁcacy categories (Table 1) based on
prescription claims in the 12 months after the index
date. Subjects in the low, moderate, and high statin
efﬁcacy categories were required to have a mini-
mum level of adherence of the same statin and efﬁ-
cacy dose. Subjects assigned to these statin efﬁcacy
categories must have had at least two statin pre-
scription claims with no more than 90 days between
prescriptions based on a 30-day supply. Subjects
with other statin use were categorized separately,
including subjects with single statin prescriptions, a
greater than 90-day gap in statin treatment, pre-
scriptions from multiple efﬁcacy categories, or com-
bination therapy with nonstatin LLMs (therapeutic
niacin, FAD, or BAS). Subjects with only nonstatin
LLMs were categorized as “other LLM use.” Sub-
jects without LLM use were also classiﬁed sepa-
rately resulting in six LLM categories: low efﬁcacy
statins, moderate efﬁcacy statins, high efﬁcacy stat-
ins, nonadherent statin use, other LLM use, and no
LLM use.
Figure 1 Diagram of study periods.
Table 1 Lipid-lowering medication efﬁcacy classiﬁcation
High-efﬁcacy statins
≥41% LDL-C reduction
Moderate-efﬁcacy statins
31–40% LDL-C reduction
Low-efﬁcacy statins 
£30% LDL-C reduction Other statin use
Other 
LLM use No LLM use
Lovastatin 40 mg BID
Cerivastatin 0.8 mg QD
Simvastatin 40 mg QD
Simvastatin 80 mg QD
Atorvastatin 20 mg QD
Atorvastatin 40 mg QD
Atorvastatin 80 mg QD
Fluvastatin 80 mg QD
Pravastatin 20 mg QD
Pravastatin 40 mg QD
Lovastatin 40 mg QD
Lovastatin 20 mg BID
Cerivastatin 0.3 mg QD
Cerivastatin 0.4 mg QD
Simvastatin 20 mg QD
Atorvastatin 10 mg QD
Fluvastatin 20 mg QD
Fluvastatin 40 mg QD
Pravastatin 10 mg QD
Lovastatin 10 mg QD
Lovastatin 20 mg QD
Lovastatin 10 mg BID
Cerivastatin 0.2 mg QD
Simvastatin 5 mg QD
Simvastatin 10 mg QD
Single statin prescriptions,
multiple efﬁcacy statin 
use, large gaps in statin 
use, or combination 
statin/nonstatin LLM use
Nonstatin
LLM use
No LLM use
References: Mevacor, Zocor, Lescol, Pravachol, Baycol, Zocor product labeling.
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Subject Characteristics and LLM Utilization
Demographics (age and sex) were obtained for each
subject. The utilization of each type of LLM was
measured in terms of number of claims, the propor-
tion of subjects with use of multiple LLMs or mul-
tiple statins, the proportion of subjects increasing
their initial dose of LLMs, and the proportion of
subjects with use of the highest dose available of
any particular statin in the 12-month period after
the index date.
Cholesterol Values
Baseline and post-treatment cholesterol test results
were determined for each subject. In the presence of
multiple test results, the most recent test result
before the index date (up to 12 months before the
index date) was used for the baseline test value and
the results from the test that occurred the farthest
from the index date (up to 12 months after the
index date) was used for the post-treatment test
value. The minimum time period after initiation of
lipid-lowering therapy and ﬁrst post-treatment
LDL-C value was 4 weeks (28 days). If the index
date reﬂected a diagnosis and not medication initi-
ation, then the minimum number of days was
imposed from the start of new drug therapy. For
subjects with no LLM use, the minimum time until
a post LDL-C value was determined from the index
date. HDL-C values were used to assess a subject’s
CHD risk status whereas LDL-C values were used
to determine the effect of treatment and subjects’
ability to reach ATP III goals. The absolute change
in LDL-C, the percent change in LDL-C, and the
subjects reaching their ATP III goals was determined
for all subjects.
Statistical Analysis
Subject demographics and the utilization of LLM
therapy was summarized and described using fre-
quency distributions and bivariate techniques. Age
was examined across LLM categories using an
ANCOVA model and a Ryan-Einot-Gabriel-Welsch
multiple range test [25] at a signiﬁcance level of
alpha = 0.05. Sex was examined similarly using a
Cochran-Mantel-Hanzsel Chi-Square test [25]. We
descriptively examined the proportion of subjects,
overall and in each risk group by LLM category.
Changes in LDL-C levels for each statin efﬁcacy
category were compared with the expected result
based on product labeling. Statistical comparisons
were made across LLM categories using a multiple
regression model. Additionally, the proportion of
subjects meeting their ATP III-established LDL-C
goal was compared across LLM categories using a
logistic regression model. Included in the statistical
equations were variables indicating the LLM cate-
gories (no LLM use was the reference group), age,
sex, the level of CHD risk (moderate or high), the
baseline (BL) LDL-C value, an indicator variable for
obesity (ICD-9278.0x) and the natural log of the
preindex total health-care cost. A log transforma-
tion was used to correct the skewed distribution of
health-care costs. Total health-care cost is a proxy
for total health-care utilization and commonly used
as an approximation a subject’s overall morbidity
burden—adding this variable to the model helps to
control for any differences in the population that
may affect the ability to reach an LDL-C goal other
than the use of LLMs [26–28]. The reference group
for the medication categories was the no LLM use
category. All statistical tests used a signiﬁcance level
of alpha = 0.05.
Results
Study Population Characteristics
We identiﬁed 39,124 newly indicated hyperlipi-
demic subjects, ≥18 years of age, considered at high
or moderate risk for CHD as previously deﬁned.
The majority of subjects were male (61.9%) and
most were enrolled in health plans in the south
Atlantic (30.2%), east north central (36.8%) and
west north central (20.5%) United States. The aver-
age age was 53.9 years (range: 18–92 years). The
majority (n = 22,048, 56.4%) of at-risk subjects
had no LLM use in the 12-month follow-up period
(Table 2). Female subjects, younger individuals, and
individuals with fewer CHD risk factors and/or
fewer chronic conditions were less likely to be on
LLMs.
Lipid-Lowering Medication Use
Statins were the most frequently prescribed LLM
(89.5% of prescriptions [97,398 of 108,830 LLM
pharmacy claims] for 90.4% of subjects on lipid-
lowering therapy [15,436 of 17,076]). The average
number of prescriptions per subject over the 12-
month period was 5.7 (SD 4.2) and 6.4 (SD 4.2) for
statins and other LLMs, respectively. The most
commonly prescribed medications were atorvasta-
tin (55.8%), simvastatin (18.6%), and pravastatin
(17.7%). Cerivastatin use was observed in 6% of
subjects (n = 1026). The recall of cerivastatin on
August 1, 2001 occurred during the follow-up
period for 355 cerivastatin users, less than 1% of
subjects. Approximately one-third of the follow-up
time for these 355 subjects was affected by this
recall. The inclusion or exclusion of subjects receiv-
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ing cerivastatin had no impact on the results of this
study.
Categorization. The 17,076 LLM-treated subjects
were classiﬁed into ﬁve LLM categories (Table 2).
Approximately 61% (n = 10,403) of LLM-treated
subjects were categorized into statin efﬁcacy cate-
gories. Approximately 51% (n = 8688) of the LLM
users were classiﬁed into the moderate efﬁcacy sta-
tin category; 6.7% (n = 1138) were classiﬁed into
the high efﬁcacy statin category and 3.4% (n = 577)
were classiﬁed into the low efﬁcacy statin category.
Thirty percent (29.5%) of LLM-treated subjects
(n = 5033) had other statin use and 9.6%
(n = 1640) were strictly nonstatin LLM-treated sub-
jects. Of the 5033 subjects with nonadherent statin
use, 40.5% (n = 2038) had a single statin prescrip-
tion, 5.1% (n = 255) had greater than a 90-day gap
between statin prescriptions, 37.5% (n = 1886) had
multiple efﬁcacy statin prescriptions, and 17.0%
(n = 854) had a combination of statin and nonstatin
prescriptions.
Based on the entire sample of moderate- to high-
CHD risk subjects with an indication of hyper-
lipidemia (n = 39,124), approximately 2.9% of the
subjects were categorized into the high-efﬁcacy
statin group, 22% in the moderate-efﬁcacy group,
1.5% in low-efﬁcacy group, 13% in the other statin
group, 4.2% were other LLM users, and 56% had
no LLM use.
Titration. Overall, 2658 of LLM-treated subjects
(15.6%) increased their statin dose either within a
statin efﬁcacy category (n = 478) or titrated up to a
higher efﬁcacy statin category (n = 2079). Of the
2079 subjects who titrated up to a higher efﬁcacy
statin category, most subjects (n = 1611, 77.5%)
moved from a moderate efﬁcacy statin to a high
efﬁcacy statin. Within statin efﬁcacy categories, the
up-titration was most common in the high-efﬁcacy
statin category (10.4%, n = 107) compared with
4.1% (n = 355) and 2.8% (n = 16) in the moderate-
and low-efﬁcacy statin categories, respectively.
Despite the fact that a number of subjects up-
titrated their statin dose, a small percentage of sub-
jects (266 of 15,436 statin users, 1.7%) were up-
titrated to the maximum statin dose. Similarly a
small percentage of subjects (394, 2.3%) had pre-
scriptions for a maximum LLM dose.
Demographics. A higher percentage of males was
observed across LLM groups compared with
females. Nevertheless, a signiﬁcantly lower percent-
age of males were in the “untreated” category
compared with the other groups (P < 0.05). Low-
efﬁcacy statin users were signiﬁcantly older than
moderate efﬁcacy statin users; and moderate efﬁ-
cacy statin users were signiﬁcantly older than all
other LLM groups, except low efﬁcacy statin users
(P < 0.05).
LDL-C Test Results and Reductions in LDL-C
Across LLM categories, 964 (2.5%) had results
both in the preindex and postindex periods and
2718 (6.9%) had a post or follow-up result
(Table 3). Subjects with LLM use had a higher
percentage of postindex results compared with
untreated subjects and statin users had a higher per-
centage of both baseline and postindex results com-
pared with nonstatin and untreated subjects. Based
on the subset of 2718 subjects with an LDL-C
Table 2 Subject characteristics, risk factors, and LDL goals by efﬁcacy category
CHD risk subjects
Efﬁcacy category 
Total 
39,124
High efﬁcacy
statins
1,138
Moderate
efﬁcacy statins
8,688
Low efﬁcacy
statins
577
Other statin
use
5,033
Other LLM
use
1,640
No LLM
use
22,048
Subjects by category (%) 2.9 22.2 1.5 12.9 4.2 56.4
Subjects with LLM use (%) 6.7 50.9 3.4 29.5 9.6
Demographics
Mean age (year) 53.9 54.7 57.2 53.6 52.7 53.6 53.9
Men (%) 64.0 64.5 62.2 65.0 62.1 60.1 61.9
Number of subjects with an LDL goal of 
<100 mg/dL: CHD and CHD-equivalent 
condition (e.g., acute MI, angina 
pectoris, peripheral vascular disease, 
diabetes) in prior 24 months
721 5,440 372 3,292 1,029 11,076 21,930
Percentage 63.4 62.6 64.5 65.4 62.7 50.2 56.1
Number of subjects with an LDL Goal of
<130 mg/dL: 2 or more other risk 
factors (e.g., tobacco use, hypertension,
history of ischemic heart disease, age 
risk) in prior 24 months
417 3,248 205 1,741 611 10,972 17,194
Percentage 36.6 37.4 35.5 34.6 37.3 49.8 43.9
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result, the mean baseline LDL-C value was 148 mg/
dL and the mean follow-up value was 116 mg/dL
(mean follow-up was 108 mg/dL for 964 subjects
with BL LDL-C value) A separate analysis was
conducted comparing the characteristics of subjects
with and without an LDL-C lab result. There were
slight variations in geographic region, however, no
signiﬁcant differences were observed in mean age,
percent male, number of specialty types, CHD risk,
and baseline health-care cost. Subjects with a base-
line LDL-C value already at goal (6.3%) were
removed from the ATP III goal analysis. Subjects
had a mean interval between their ﬁrst LLM pre-
scriptions and their latest LDL-C value (the test
value used to assess the effectiveness of LLM ther-
apy) of 215 days (SD 100 days, median 226 days).
For the 964 subjects with a baseline and follow-up
LDL-C value, the mean change from baseline was
-39.8 mg/dL and the mean percent change from
baseline was a 22.9% decrease in mg/dL. Baseline
LDL-C values were highest for statin users and low-
est for nonstatin-treated subjects. Among all statin
users, mean baseline LDL-C levels ranged from 149
to 164 mg/dL compared with subjects with other
LLM use (mean 109.6 mg/dL) and subjects with
no LLM use (mean 133.6 mg/dL). Subjects treated
with statin therapy had a greater change and
percent change from baseline in LDL-C values com-
pared with nonstatin LLM users and non-LLM-
treated subjects. The statin-treated groups had
absolute reductions ranging from a mean decrease
of 32.3 mg/dL in the low-efﬁcacy statin group to a
decrease of 57.3 mg/dL in the high-efﬁcacy statin
group. Percent reductions ranged from a 19.1% to
a 31.6% reduction from baseline. The mean percent
reduction for the high- and moderate-efﬁcacy statin
group was below expectations based on package
labeling. The median percent change from baseline
of a 37.0% decrease in mg/dL for the high-efﬁcacy
subject states that less than half the subjects in this
group met the expected reduction of >41%. The
absolute reductions and percent reductions in the
high- and moderate-efﬁcacy groups were approxi-
mately twice as high as those in the non-LLM-
treated subjects. The nonstatin LLM-treated
subjects had, on average, an increase in LDL-C
levels from baseline; though many (22.8%) non-
statin LLM-treated subjects were below ATP III
goals before LLM initiation (mean baseline LDL-C:
109.6 mg/dL). Table 3 also presents the least-
squares (LS) mean percent reductions in LDL-C
adjusted for other variables in an ANOVA model.
The LS mean reductions for the high-efﬁcacy and
moderate-efﬁcacy statin groups were greater (more
negative) than the LS mean for the non-LLM-
treated group, whereas the LS means of the low-efﬁ-
cacy, other statin, and other LLM groups were less
negative that the non-LLM-treated group LS mean.
In the regression model (Table 4), the dependent
variable was change from baseline and because a
greater negative value was favorable, a negative
parameter estimate indicates a positive association
with reduction in LDL-C. Subjects in the moderate-
efﬁcacy statin groups had signiﬁcantly greater per-
cent reduction from baseline compared with the
non-LLM-treated group (est = -0.040, P = 0.0376).
The estimate for the high-efﬁcacy group was nega-
tive suggesting a greater percent reduction than the
non-LLM-treated group, but the statistical test was
not signiﬁcant (P = 0.6644). Based on alpha = 0.05
and power = 0.80, a sample size of approximately
150 per treatment arm would be needed to show a
signiﬁcant reduction of 10% in this study. The non-
LLM use group had a signiﬁcantly greater percent
reduction in LDL-C compared with the other statin
use and the other LLM use groups. Also in this
model, males had an approximately 0.7% greater
percent reduction in LDL-C compared with females
Table 4 Multiple regression model to predict percent change in LDL-C result
Parameter Parameter SE t P value
Intercept 0.593 0.071 8.36 <0.0001
Sex (male = 1) -0.069 0.016 -4.38 <0.0001
Age -0.002 0.001 -2.31 0.0211
Baseline LDL-C value -0.004 0.000 -18.93 <0.0001
NCEP III LDL goal (<100 = 1) -0.032 0.016 -1.99 0.0467
Baseline total health-care cost (log) -0.006 0.004 -1.58 0.1149
Obesity diagnosis -0.006 0.038 -0.15 0.8671
Treatment groups
High efﬁcacy statin -0.016 0.038 -0.43 0.6644
Moderate-efﬁcacy statin -0.040 0.019 -2.08 0.0376
Low efﬁcacy statin 0.052 0.050 1.04 0.3006
Other statin use 0.059 0.022 2.67 0.0077
Other LLM use 0.211 0.037 5.64 <0.0001
Overall Model Statistics: F15,948 = 36.56; P < 0.0001; Adjusted R2 = 0.3565.
Untreated (No LLM use) was used as reference category and does not appear in the model.
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(est = -0.069, P < 0.0001), an increase in age was
associated with a greater reductions in LDL-C
(est = -0.002, P = 0.0211), a higher BL LDL-C
value was associated with a greater reductions in
LDL-C (est = -0.004, P < 0.0001), and a lower ATP
III goal was associated with a greater LDL-C reduc-
tion (est = -0.032, P = 0.0467). For the subjects
without BL LDL-C values, the mean BL LDL-C
value within the efﬁcacy group was used in this
analysis.
Risk Factors and LDL-C Goal
Fifty-six percent of subjects (21,930 of 39,124) had
either a CHD or a CHD-equivalent condition in
their medical claims, and therefore had an LDL-C
goal of <100 mg/dL (Table 2). The remaining
43.9% (17,194 of 39,124), had two or more CHD
risk factors and therefore had a goal of <130 mg/
dL. Of the subjects with LLM therapy, a similar per-
centage (63%-65%) in each LLM category had
either an established CHD or CHD-equivalent con-
dition, in contrast to the group of subjects with no
LLM therapy, in which 50% of subjects had an
established CHD or a CHD-equivalent condition.
Subjects reaching ATP III LDL-C goal. Less than
half of subjects for whom laboratory results were
available reached ATP III goals (46.8% [1191 of
2718]) (bottom half of Table 3). A greater propor-
tion of subjects in the high-efﬁcacy category reached
goal (71.6% vs. 43.1%) compared with other drug
efﬁcacy groups (including the non-LLM group).
There was a graded association between statin efﬁ-
cacy level and the proportion of subjects reaching
goal with more efﬁcacious treatment leading to
more successful outcomes. Low-efﬁcacy statin users
had a similar percentage of subjects reaching goal
(43.4%) compared with the other statin users
(44.4%) and the other LLM users (45.9%). For the
non-LLM use group, 38.2% had LDL-C levels
within goal.
In the logistic regression analysis (Table 5), the
high-efﬁcacy, moderate-efﬁcacy, and other statin
groups had signiﬁcantly higher odds of subjects
reaching their ATP III LDL-C goal compared with
subjects with no LLM use (P < 0.05). High-efﬁcacy
statin users were more than four times more likely
to reach goal then non-LLM-treated subjects. The
odds of reaching goal increased as statin efﬁcacy
increased. Also in the model, males were more likely
to reach goal than females (odds ratio
[OR] = 1.256, P = 0.0112), a higher BL LDL-C
value was associated with lower odds of reaching
goal (OR = 0.994, P = 0.0189), a lower ATP III goal
was associated with lower odds of reaching goal
(OR = 0.291, P < 0.0001), and a higher baseline
total health-care cost increases the likelihood of
reaching goal (unit increase in cost OR = 1.112,
P < 0.0001).
Within-risk-group analysis. Table 6 provides a sub-
set analysis of the percentage of subjects reaching
ATP III LDL-C goals by risk category. In this
descriptive analysis, a higher percentage of subjects
at moderate risk for CHD (goal <130 mg/dL)
reached goal than high-risk subjects (goal <100 mg/
dL) (55.2% vs. 36.3%). In the high-risk subjects,
the proportion of subjects reaching goal increased
with more aggressive treatment, however, a linear
pattern was not observed in the moderate-risk
group. Table 6 shows that approximately 45% (26
of 47) of high-risk subjects who were treated with
high-efﬁcacy medication did not reach a goal of
<100 mg/dL and more than half of each the other
LLM-treated subjects in the high-risk group did not
reach this goal. Of subjects with available labora-
tory values who were in the high-risk group, 39%
(604 of 1541) were not treated with LLMs.
Table 5 Multiple logistic regression model to predict ATP III LDL-C goal
Parameter Parameter SE Chi-square P value Odds Ratio
Intercept -0.050 0.505 0.01 0.9208
Sex (male = 1) 0.228 0.090 6.43 0.0112 1.256
Age 0.001 0.001 0.05 0.8208 1.001
Baseline LDL-C value -0.006 0.003 5.12 0.0189 0.994
NCEP III LDL goal (<100 = 1) -1.233 0.094 172.95 <0.0001 0.291
Baseline total health-care cost (log) 0.106 0.025 18.19 <0.0001 1.112
Obesity diagnosis 0.304 0.198 2.36 0.1244 1.355
Treatment groups
High efﬁcacy statin 1.485 0.267 31.00 <0.0001 4.413
Moderate-efﬁcacy statin 1.099 0.116 89.56 <0.0001 3.000
Low efﬁcacy statin 0.549 0.298 3.39 0.0656 1.731
Other statin use 0.568 0.135 17.67 <0.0001 1.765
Other LLM use 0.374 0.227 2.71 0.0999 1.454
Hosmer and Lemeshow Goodness-of-Fit test: c2 = 8.023, df = 8, P = 0.4312; c = 0.689.
Untreated (No LLM use) was used as reference category and does not appear in the model.
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Inconsistent Statin Use
Of the subjects with a baseline LDL-C values,
35.9% (346 of 964) of subjects needed at least a
30% reduction in LDL-C value to meet their goal.
Only 53.5% (185 of 346) of the subjects received
either moderate- or high-efﬁcacy statins. Approxi-
mately 16% of subjects needed at least a 40%
reduction in LDL-C value to meet their goal and
only 2.0% (3 of 149) of the subjects received high-
efﬁcacy statins. Notably, 50% of subjects who were
identiﬁed as being at high risk for CHD (as deﬁned
by ATP III) had no evidence of LLM use.
Discussion
The main ﬁndings of this study were the lack of
effectiveness of statin therapy and undertreatment
among high-risk individuals. Effectiveness of a med-
ication may be due to the insufﬁcient potency of a
medication as well as a lack of adherence. Medica-
tion adherence analyses were reported by Frolkis
and colleagues suggesting that variability in patient
adherence may contribute to the lack of expected
LDL-C reductions [24]. We used a methodology to
categorize subjects into medication groups that
required a minimum level of adherent statin use, yet
the resulting effectiveness was below LDL-C reduc-
tions stated in the package labeling. Approximately
30% of the statin users did not meet our adherence
requirements, and the medication possession ratio
(MPR = total days supply in the year follow-up
divided by 365 days) of the statin efﬁcacy groups
ranged from 59% to 65%, compared with an MPR
of 50% for the other statin use group and an MPR
of 46% for the other LLM use group. The lack of
effectiveness–ability of statin medications in real-
world observations to achieve the observed efﬁcacy
reported in clinical trials—may be a result of under-
prescribing of the appropriate strength of therapy,
but may also be due to adherence to medications.
Previous research has also noted the failure of
subjects in clinical practice settings to achieve
expected reductions in LDL-C when treated with
statin therapy [8,9,13]. Subjects enrolled in proto-
col-driven RCTs have scheduled visits and are care-
fully screened, monitored closely, and are likely to
have higher medication compliance than that seen
in a real-world setting.
Retrospective cohort studies using administrative
claims data enhanced with laboratory results can
be used to supplement clinical trials data and to
enhance the generalizability of the ﬁndings to real-
world practice. In this study, the mean baseline
LDL-C value was 148 mg/dL and the mean follow-
up value was 116 mg/dL. This mean baseline value
was higher than the mean value of LDL-C for all US
adults reported by NHANES III of 127 mg/dL [1],
although this NHANES ﬁgure represents all US
adults, whereas the baseline mean LDL-C in this
study was among moderate to high CHD risk
subjects.
The percent change in LDL-C reduction results
suggests that the lack of effectiveness appears to be
more evident in the high-efﬁcacy statin users and
the unmet need appears to be more evident in the
high-risk population. In the three statin efﬁcacy
groups that required a minimum level of adherence,
a dose–response relationship was observed, but less
than half of subjects in the high-efﬁcacy group
achieved LDL-C reductions stated in the package
labeling and only 68% reached their LDL-C goal
during a one-year follow-up period. While the
subset of subjects with an existing CHD or CHD-
equivalent condition that received statin therapy
achieved reductions in LDL-C values consistent
with package labeling, less than 60% of the high-
efﬁcacy statin users reached their ATP III goal of
<100 mg/dL and less than 50% of other statin
groups reached goal. More strikingly, only 50% of
subjects with CHD or CHD-equivalent conditions
received LLMs and less than 30% of subjects with
CHD or CHD-equivalent conditions had statin
therapy consistent with our deﬁnitions of the statin
efﬁcacy categories. This study was based on ATP III
guidelines in which one of the new features was to
include persons with diabetes to the risk level of
CHD risk equivalent. The high proportion of sub-
jects without LLM use in the subset of subjects with
an existing CHD or CHD-equivalent condition may
be a result of this new ATP III feature. The average
age of the subset of subjects with an existing CHD
or CHD-equivalent condition was 52.8 years of age
compared with an average age of 55.2 years in the
subset of subjects with two or more CHD risk fac-
tors also suggests that a younger set of persons with
diabetes were included in this group.
The ATP III guidelines created a greater need for
lipid-lowering therapy for high-risk patients and
these results suggest that this need is unmet. A pre-
vious study (Dubois et al.), also based on ATP III
guidelines, concluded that there did not appear to
be extended use of statins in a population with
lower cardiovascular risk [29]. Therefore, efforts to
increase the use of stain therapy appear to be
focused appropriately on the higher-risk patients,
though many high-risk patients still fail to receive
treatment or adequate treatment.
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This retrospective study has several limitations.
First is the possibility of misclassiﬁcation of new
hyperlipidemic subjects and the determination of
ATP III goals. To be included in the study subjects
had to be free of hyperlipidemia before January 1,
1999. Because we had information on prescription
claims and disease diagnoses for a 24-month period
before ﬁrst indication of a hyperlipidemia diagnosis
or initial LLM use (index date), we did not have lab-
oratory values before January 1, 1999 and the lack
of information on HDL levels may have affected the
assessment of risk factors and ATP III goals. We
used actual lipid values and diagnoses on nonlabo-
ratory claims to classify hyperlipidemic subjects and
their risk level. It is unlikely that a subject would be
classiﬁed as a false positive and therefore the inci-
dence of hyperlipidemia and the level of CHD risk
would, if anything, be under-reported. Under-
reporting the level of risk would only accentuate the
issue of undertreatment. Second, a limitation com-
mon to most studies using administrative claims
data and laboratory results was the lack of choles-
terol laboratory values for a large proportion of the
sample. Of the 43.6% (17,076 of 39,124) of sub-
jects that received LLMs, 9.1% (1550 of 17,076)
had LDL-results after medication initiation. Only
2.5% (964 of 39,124) had both pre- and post-
treatment LDL-C results. We examined the popula-
tions with and without lab values and found that
similar characteristics existed in terms of age, sex,
obesity, and CHD risk; however, the subjects with-
out lab values had lower LLM adherence than the
subjects with lab values. This would lead us to
believe that the level of LLM effectiveness is worse
than reported in this study. This is a major limita-
tion of the study and while further research with
larger samples is suggested, these results do suggest
an issue with lack of LLM effectiveness and
undertreatment. Finally, the study requirement of
36 months of continuous enrollment may have
limited generalizability (i.e., to those with chronic
conditions unlikely to switch health plans, those
who survived, and older subjects).
Conclusions
The results of this real-world study of the effective-
ness of statin therapy are consistent with previously
reported ﬁndings that hyperlipidemia management
needs further improvement [8–12,29]. The reduc-
tions in LDL-C values in subjects treated with stat-
ins generally follow a dose–response relationship,
but there are concerns with the high percentage of
untreated high-risk subjects, the effectiveness of the
strongest statin doses in achieving desired LDL-C
reductions and getting to goal, and the insufﬁcient
amount of dose titration, especially from the lower-
efﬁcacy agents. There is evidence of a need for more
extended use of statin therapy in populations with
higher cardiovascular risk and for more efﬁcacious
agents on which subjects can reach their cholesterol
goal at the starting dose, without the need to titrate
or augment with combination therapy.
Source of ﬁnancial support: AstraZeneca LP, Wilmington,
DE, USA.
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